Cutaneous reactions to STI571 [2]

New England Journal of Medicine

Volumn 345, Issue 8, 2001, Pages 618-619

  Brouard, M ^a   Saurat, J H ^a  

^a Faculty of Medicine   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG SAFETY; EXFOLIATIVE DERMATITIS; HUMAN; LETTER; LEUKEMIA; PRIORITY JOURNAL; PUSTULOSIS; RASH; SKIN TOXICITY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG ERUPTION; NOTE;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; EXANTHEMA; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0035939714     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200108233450814     Document Type: Letter

References (5)

1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
2. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
3. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia
4. Acute generalized exanthematous pustulosis: Analysis of 63 cases
5. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor